# EVOLVING VIRUS-SPECIFIC sACE2 MIMICS FOR COMPETITIVE INHIBITION OF SARS-CoV-2

> **NIH NIH R21** · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2020 · $399,346

## Abstract

PROJECT SUMMARY
The rapid spread of the highly-pathogenic, novel SARS-coronavirus 2 (SARS-CoV-2) has caused a global
health emergency. Thus, there is a desperate need for effective antiviral therapeutics to counteract this virus.
The SARS-CoV-2 virus enters cells using the ACE2 receptor1 which binds the viral spike protein2. In its
soluble form, ACE2 (sACE2) has the potential to be used as a stable and non-immunogenic competitive
inhibitor to SARS-CoV-2 and is presently being explored in clinical trials3. Due to the potential negative side
effects of anti-spike mAbs18, and the fact that ACE2 exhibits other biological roles4–6 including integrin
signaling regulation7,8, spike-specific receptor mimics would yield novel therapeutics for SARS-CoV-2 and
potentially other highly infectious diseases.
This proposal seeks to use machine learning and directed evolution to develop high affinity, yet
endogenously-inactive mimics of sACE2 in order to create rapidly implementable therapeutics to combat
SARS-CoV-2 and potential corona-like viruses. This approach would allow for the generation of scalable and
translatable biologics, and provide a platform to rapidly course-correct for potential mutations that may arise
in the future. Utilizing deep-learning with UniRep49, will design and generate sACE2 variants that tightly bind
the SARS-CoV2-2 spike protein but do not cross-interact with endogenous targets such as integrins [Aim 1].
Simultaneously, we will perform directed evolution to optimize spike-binding and select against variants that
bind endogenous proteins [Aim 2]. Finally, we will identify lead candidates and evaluate the tolerance and
immunogenicity of engineered sACE2 variants in mice [Aim 3]. Collectively, this proposal will develop
highly-specific ACE2 receptor mimics in order to create novel antivirals with minimal immunogenicity in time
to save lives and prevent future outbreaks.
10

## Key facts

- **NIH application ID:** 10175307
- **Project number:** 1R21AI158169-01
- **Recipient organization:** MASSACHUSETTS INSTITUTE OF TECHNOLOGY
- **Principal Investigator:** Kevin Esvelt
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $399,346
- **Award type:** 1
- **Project period:** 2020-09-01 → 2023-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10175307

## Citation

> US National Institutes of Health, RePORTER application 10175307, EVOLVING VIRUS-SPECIFIC sACE2 MIMICS FOR COMPETITIVE INHIBITION OF SARS-CoV-2 (1R21AI158169-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10175307. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*